Results 151 to 160 of about 144,570 (357)

Impairment of human spatial orientation in the horizontal, but not the vertical plane, due to aging, cognitive decline, or chronic peripheral vestibular loss

Frontiers in Aging Neuroscience
IntroductionHumans and other vertebrates exhibit anisotropic orientation and navigation skills, with better performances in the horizontal compared to the vertical plane. While horizontal navigation accuracy decreases with higher age, less is known about
Johannes Gerb, Johannes Gerb, Vivien Oertle, Burak Onmus, Marianne Dieterich, Marianne Dieterich, Marianne Dieterich, Marianne Dieterich, Thomas Brandt, Thomas Brandt   +9 more
doaj   +1 more source

On Cases of Simple Vertigo [PDF]

, 1873
T. C. Allbutt
openalex   +1 more source

Drugs and vertigo

, 1991
The list of drugs that may have adverse effects on hearing or balance is impressive (see also Chap. 24). It includes anaesthetics, anticonvulsants, antidepressants, analgesics, antidiabetics, antihypertensive agents, anti-inflammatory drugs, contraceptives, cytotoxic agents, cardiovascular drugs, sedatives, and tranquillizers (Table 28.1; Ballantyne ...
openaire   +2 more sources

The Pathway to Proof‐of‐Concept for BNC210, a Negative Allosteric Modulator of the Alpha‐7 Nicotinic Acetylcholine Receptor (nAChR), for Treatment of Psychiatric Disease

Clinical Pharmacology in Drug Development, EarlyView.
Abstract BNC210 is an investigational small molecule selective negative allosteric modulator of the alpha‐7 nicotinic acetylcholine receptor (α7 nAChR). It is an anxiolytic compound with a novel mechanism of action. In a series of Phase 1 clinical trials in healthy volunteers, psychometric test batteries showed that BNC210 did not cause attention ...
Paul Rolan, Elizabeth Doolin, Dharam Paul, Julia Crossman, Michael Odontiadis, Philippe Danjou, Mark Smith, Spyros Papapetropoulos   +7 more
wiley   +1 more source

Ocular Vertigo of Interest to the General Practitioner [PDF]

, 1905
Benjamin P. Croft
openalex   +1 more source

A Phase 1, Randomized, Open‐Label, Parallel Group Study to Evaluate the Relative Bioavailability and Safety of Subcutaneous Bepirovirsen when Delivered from a Vial or Prefilled Syringe Fitted with a Safety Syringe Device in Healthy Adult Participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Bepirovirsen, an antisense oligonucleotide in development for the treatment of chronic hepatitis B virus (HBV) infection, is administered from glass vials as a subcutaneous (SC) injection by healthcare professionals (HCPs). A ready‐to‐use prefilled syringe (PFS) assembled with a safety syringe device (SSD) has been developed to make ...
Amir S. Youssef, Poonam Shah, Maxwell Hu, Helene Plein, Abhishek Roy, Ravi Sharma, Sarah Mole, Magdalena Blazejczyk, Wendy Cross, Brian Spears, Samuel Pak, Rejbinder Kaur, Robert Elston, Dickens Theodore, Marjan Hezareh, Ahmed Nader   +15 more
wiley   +1 more source

Intra-Tympanic Disease as a Factor in the Causation of Aural Vertigo [PDF]

, 1897
CLARENCE J. BLAKE
openalex   +1 more source

Safety and Efficacy of the NMDA‐2b‐Selective Negative Allosteric Modulator BI 1569912: A Phase Ib Randomized Trial in Major Depressive Disorder

Clinical Pharmacology &Therapeutics, EarlyView.
Selective N‐methyl‐D‐aspartate receptor subunit 2b negative allosteric modulators (NR2B NAMs) are being explored as potential new treatment options for major depressive disorder (MDD). This Phase Ib, randomized, double‐blind, placebo‐controlled, parallel‐group trial was conducted in adults (N = 59) with moderate‐to‐severe MDD and insufficient response ...
Roger S. McIntyre, Gerard Sanacora, David P. Walling, Elan A. Cohen, Shishuka Malhotra, Holger Rosenbrock, Manuela Schmitz, Andreas Scholz, Sigurd D. Süssmuth, Franco De Crescenzo   +9 more
wiley   +1 more source

Safety, Pharmacokinetics, and Pharmacodynamics of Osivelotor for Sickle Cell Disease: First‐in‐Human Studies in Healthy Participants and Patients

Clinical Pharmacology &Therapeutics, EarlyView.
The investigational agent osivelotor, a small molecule hemoglobin (Hb) modifier in development for the treatment of sickle cell disease (SCD), acts by increasing Hb‐oxygen affinity and inhibiting the polymerization of sickle Hb. We report safety, pharmacokinetic (PK), and pharmacodynamic (PD) data from the first two phase 1 clinical trials of ...
Eleanor A. Lisbon, R. Clark Brown, Andrew Redfern, Ken Duchin, Aline Barth, Erika S. Roberts, Polo Gaputan, Kobina Dufu, Arthur Lo, Mira Patel Pochron, David R. Archer, Wai Chin, Karena Kong, Carla B. Washington, Adeyemi Adenola, Eric I. Zimmerman   +15 more
wiley   +1 more source

ARTERO-SCLEROTIC VERTIGO [PDF]

, 1890
NULL AUTHOR_ID
openalex   +1 more source